Christopher M. Haqq
Intarcia Therapeutics (United States)(US)
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, Immunotherapy and Immune Responses, TGF-β signaling in diseases, CAR-T cell therapy research, Pancreatic and Hepatic Oncology Research
Most-Cited Works
- → Abiraterone and Increased Survival in Metastatic Prostate Cancer(2011)4,364 cited
- → Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study(2012)1,374 cited
- → The gene expression signatures of melanoma progression(2005)432 cited
- → Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer(2010)409 cited
- → Cell- and gene-specific regulation of primary target genes by the androgen receptor(2007)345 cited
- → Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention(2008)304 cited
- → Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial(2012)279 cited
- → Intense Androgen-Deprivation Therapy With Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study(2014)275 cited
- → A conditional feedback loop regulates Ras activity through EphA2(2005)263 cited
- → The unique transcriptome through day 3 of human preimplantation development(2004)246 cited